WANTAI BIOLOGICAL(SH:603392) news flash·2025-07-09 00:09Core Viewpoint - The announcement of the pricing for the first domestically produced nine-valent HPV vaccine "Xinkening®9" by Wantai Biological Pharmacy, priced at 499 yuan per dose, represents a significant development in the HPV vaccine market in China, being approximately 40% cheaper than imported alternatives [1] Company Summary - Wantai Biological Pharmacy has launched "Xinkening®9", the first domestic nine-valent HPV vaccine in China and the second globally [1] - The vaccine is designed to prevent infections from seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), along with related diseases [1] Industry Summary - The pricing strategy of "Xinkening®9" at 499 yuan per dose positions it competitively against imported nine-valent HPV vaccines, which are significantly more expensive [1] - This development may enhance access to HPV vaccination in China, potentially increasing vaccination rates and public health outcomes [1]